CagriSema Supplier China: Blend Buyer Guide

Define CagriSema as a two-component blend

Write both component names, each nominal content, the total content, ratio, material form, quantity and RUO status. Do not treat CagriSema as one molecular identity or allow the blend nickname to replace component-level specifications. Require a controlled SKU for each configuration and reconcile it across the quote, COA, analytical attachments, label and packing list. The buyer should also distinguish this blend from standalone Cagrilintide or Semaglutide and prohibit component or ratio substitutions.

Interpret 2.5 plus 2.5 and 5 plus 5 correctly

The 2.5mg + 2.5mg presentation totals 5mg, while the 5mg + 5mg presentation totals 10mg. Write every component value and unit rather than only the total. Record vial count, total quantity of each component, ratio tolerance, fill tolerance, lot and price basis. Ask whether the total refers to active component content or total lyophilized mass. This prevents a 5mg label from being misread as 5mg of each component or a 10mg label from obscuring the ratio.

Demand component-specific identity evidence

A blend purity result may not establish that both intended components are present in the correct identities and proportions. Ask which methods distinguish Cagrilintide from Semaglutide, how each identity is supported, and how quantitative composition or ratio is assessed. Review sample ID, chromatograms and mass information where applicable, specifications, dates, report numbers and approval. Require the analytical sample to connect to the exact blended batch and finished configuration being offered.

Audit blending, filling and lot genealogy

Identify the incoming component lots, blend batch, fill batch and finished lot. Ask how dispensing, mixing, homogeneity, yield and reconciliation are controlled and how rejected or remaining material is handled. If the two strengths share component lots, preserve the genealogy separately. A COA for either standalone component does not by itself qualify the finished blend. The buyer's release review should cover component records plus the blend-specific tests and finished-unit content evidence.

Compare MOQ, packaging and repeat-batch control

Clarify whether MOQ applies per blend strength, kit, batch or mixed order. Approve labels that show both component names and individual amounts, the lot and RUO wording. Confirm units per kit, secondary packaging, released stock, production and document lead time, shipping term and change notification. For repeat procurement, require review of every new blend lot and notification before a component source, method, blending process, fill operation, label or package changes.

Map accountability before supplier approval

Document the legal seller, manufacturing site, analytical laboratory, filling or packaging site, inventory owner, release authority and dispatch entity for the exact SKU. A supplier may coordinate qualified partners, but the arrangement and responsibilities must be transparent. Ask who retains original records, investigates deviations and authorizes corrections. Require notification before a critical party changes. This map separates technical control from a generic factory claim and identifies who is accountable when a report, label, package or received quantity does not match the approved purchase order.

Build one comparable wholesale quotation matrix

Send every supplier the same fields: exact identity, strength, vial count, total material, target purity, identity method, quantitative-content basis, offered lot, testing status, packaging, documents, lead time and shipping term. Mark missing answers as exceptions rather than filling gaps with assumptions. Separate one-time testing or setup costs from recurring unit costs. This creates one auditable decision record for scientific, purchasing and quality reviewers and prevents the lowest-looking offer from winning simply because it describes less work.

Apply a batch-focused quality-control review

Define methods and acceptance criteria before purchase. HPLC commonly supports chromatographic purity and mass spectrometry can support identity, but neither should imply untested attributes. Check sample identifiers, dates, report numbers, units and lot relationships. Use the quality-control framework to connect each claim to evidence. Preserve original reports, record revisions and investigate contradictions before accepting the lot.

Create a documentation gate before dispatch

List the required COA, analytical attachments, SDS, specification, supported storage statement, label proof, invoice and packing list in the RFQ. Reconcile product, strength, lot, quantity and revision across documents using the documentation guide. The importer remains responsible for current destination rules. Research-use wording supports clarity but neither guarantees customs entry nor replaces destination-specific due diligence.

Qualify logistics and receiving controls

Confirm dispatch location, carrier, shipping term, packaging configuration and realistic production, release and transit windows. Reject promises of guaranteed clearance or misleading declarations. On receipt, record package condition, seals, product, strength, lot and quantity, then link internal inventory to the supplier batch. Quarantine unexplained discrepancies until a documented quality decision is completed.

Use actual performance for repeat-order approval

A controlled evaluation order should use the same specification planned for wholesale scale. Assess document accuracy, package condition, delivery time, communication and corrective response, and consider buyer-arranged testing appropriate to risk with documented sample custody. For every new lot, repeat the batch review. Require notification before changes to manufacturing, testing, filling, material specification, labels or packaging.

Related products and same-category guides

• CagriSema 2.5mg + 2.5mg
• CagriSema 5mg + 5mg
• Cagrilintide Supplier Guide
• Semaglutide 10mg Quality Guide

Frequently asked questions